About 40 percent of American adults with obesity who try GLP-1 drugs like semaglutide lose more than 15 percent of their body weight — numbers that would have seemed impossible from a pill or injection just a decade ago. Stanford Medicine’s 2026 breakdown of the science behind these drugs is one of the cleaner explainers out there, and it lands at exactly the right moment — when everyone from your coworker to your cardiologist seems to have an opinion on Ozempic, Wegovy, and Zepbound.
Here’s what the actual science says, stripped of the celebrity noise.
How do GLP-1 drugs actually make you lose weight?
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases naturally after you eat. It tells your brain you’re full, slows how fast your stomach empties, and nudges your pancreas to release insulin. The drugs mimic that hormone, but stronger and longer-lasting than anything your body produces on its own.
Semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (Zepbound) work on receptors in the brain’s hunger centers. They don’t burn fat directly. They make you want less food. That distinction matters more than most people realize. These aren’t stimulants. They’re not suppressing appetite through brute force — they’re essentially reprogramming the signal your brain gets after a meal.
Tirzepatide goes further, targeting both GLP-1 and GIP receptors simultaneously. Clinical trials show it produces greater average weight loss than semaglutide alone — sometimes reaching 20 to 22 percent of body weight over 72 weeks. That’s not a rounding error. That’s medically significant weight reduction.
What are the real side effects — and how bad do they get?
Nausea is the most common complaint, especially in the first few weeks. Vomiting, diarrhea, and constipation show up too. Most people describe it as manageable. A smaller percentage stop the medication entirely because of it.
The more serious concerns get discussed less. Muscle loss is real — people on GLP-1s who aren’t doing resistance training can lose lean muscle mass alongside fat, which creates its own downstream problems. Pancreatitis is rare but documented. There’s ongoing research into thyroid cancer risk, though current evidence in humans remains inconclusive. Anyone with a personal or family history of medullary thyroid carcinoma should not be using these drugs — that’s not a disclaimer buried in fine print, that’s a clinical contraindication.
There’s also the rebound effect. Stop the drug, and the hunger signals come back. Most people regain a significant portion of lost weight within a year of stopping. GLP-1s appear to require long-term or indefinite use for sustained results — which has enormous implications for cost, access, and how we categorize obesity as a condition.
Is the safety profile strong enough to trust at scale?
For most people who qualify — those with a BMI over 30, or over 27 with a weight-related condition — the risk-benefit math looks favorable. Cardiovascular outcomes data for semaglutide is genuinely encouraging. The SELECT trial showed a 20 percent reduction in major cardiac events in people with obesity who had existing heart disease. That’s not a soft endpoint. That’s hard clinical outcome data.
But “safe for most” is doing a lot of work in that sentence. The long-term safety data beyond five years is still thin. These drugs are being prescribed at massive scale, in 2026, to people whose full health profiles vary wildly. The off-label use — people without obesity using GLP-1s for cosmetic weight loss — operates in murkier territory where the risk calculus looks different.
There’s a class dimension here that’s hard to ignore. At over a thousand dollars a month without insurance, GLP-1s are largely accessible to people with good coverage or disposable income. The same tech-accelerated culture that made AI-powered tools feel democratic has not touched pharmaceutical pricing. Ozempic didn’t break those barriers. It exposed them.
The science on GLP-1s is more solid than the discourse around them. But the harder questions — about long-term use, equitable access, and what it means to medicate a condition shaped by food systems and economics — are going to follow this drug class into whatever version of America comes next.
Watch for the FDA’s next round of post-market safety requirements and whether insurers move toward permanent coverage classifications — those decisions will determine whether GLP-1s become a public health tool or remain a prescription perk for the well-insured.